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Abstract--The paper describes an extremely concise mathematical model specifying quantitatively the 
influence xerted on the age-dependent patient survival probability z(t), or output function, by the time 
distribution of the cytostatic treatment f = dF/dt or input functions, F being the total dose administered. 
The model consists of a set of only four simultaneous linear differential equations of first order where 
a realistic representation is provided for all main causal connections occurring within the host-cancer 
system throughout i s lifespan. 
The peculiar circumstances where (i) no cancer disease is present, or (ii) no cytostatic treatment is
administered (i.e. F -- 0 for any t) or (iii) neither the cancer is present, nor the treatment is given, become 
simply special mathematical cases of the general differential problem outlined. Following the model 
described here, the choice of the time distribution of the cytostatic treatment becomes mathematically 
defined as an optimal control problem. 
1. INTRODUCTION 
The problem of the optimal time distribution of the highly harmful antineoplastic therapy has been 
investigated in detail by many authors and from various viewpoints in the last few years [1-13]. 
In the present paper a further attempt is made to quantify the long-term balance of the biological 
costs and benefits induced by the cytostatic treatments within the whole host-cancer system. In 
other words a mathematical model is defined, by means of which it should become possible to 
establish, at least with a large statistical uncertainty, the change in the duration of patient survival 
produced by any fixed amount dF of cytostatic treatment administered on any particular day. 
Obviously such a diagram, i.e. that expressing the lifespan as a function of the dose of cytostatic 
agent (Fig. 1), should increase, at least in the range of very low doses--unless we believe that all 
cytostatic treatments, without exception, are always harmful--should reach a well-defined maxi- 
mum at some point, viz. when the independent variable corresponds exactly to the daily optimal 
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Fig. 1. Behavior of the mathematically expected survival (average survival) in the case of a 40-year-old 
patient with a neoplastic cell mass of 100 g with a doubling time of 0.25 years after a single total exposure 
to various doses of cytostatic treatment. Each value of the survival was obtained as the average of a 
survival distribution (see Fig. 2), simulated by means of the model summarized in Fig. 3. 
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Fig. 2. Actuarial distributions expressing the time-dependent survival probability for the hypothetical 
patient in Fig. 1 after administration of various doses of cytostatic treatment in a single total body 
exposure. The eight functions were computed by means of the model in Fig. 3. Model parameters: 
P = 4.456; Q = 0.07872; L = 0.02844; Z = 3.73E-04; R = 4.346; A = 2.772; B = 3E-03; W ffi 5E-0.4; 
D = 0.01; E = 26.089; V = IE-03; C = B: Y =4.346. Initial conditions: patient age at the diaBnosis 
t0=40; neoplastic mass at diagnosis Wo=W(to)=lOOg;  age at onset of the disease tb=30.282; 
r b = r(tb) = 0.821432; r o = r ( to )  = 0.680659; ideal r0-value = 0.686826. 
thus expressing the a lmost  instantaneous ki l l ing effect o f  extremely h igh amounts  o f  cytotoxic  
poisons,  radiat ions included. 
A d iagram o f  this k ind might  actual ly b¢ obta ined by eva luat ing the average survival  t imes after 
var ious doses F o f  cytostat ic  treatment,  g iven in a single administrat ion,  i f  at each dose we had 
already establ ished exact ly the form o f  the corresponding acturial funct ion (Fig. 2), i.e. the 
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Fig. 3. Mathematical model of the host-cancer system. The same numerical values of the 10 parameters 
shown here imply the results displayed inFigs 1, 2, 4, 5, 9. A detailed explanation f the model is given 
in the text (t = age in y; F = dose in rein-equivalent). Other capital letters denote model parameters. 
Sample data: A = 2.772; B = 0.00300; P = 4.456; Q = 0.07872; L = 0.02844; V = 0.001; W = 0.001)5; 
C = B; D =0.01; E =26.089; Z =0.000373; R =4.346; Y= R. Initial conditions: t o =40y; r~ = 
r(tm~) = r(PQ/L-  Q)= 1, whence r(to)=0.6868; W(to)= 50g; y(to)= 1, Z(to)= 1. After the model 
outlined here the choice of the function f(t), i.e. the question concerning the protocols of administration 
of cytostatic treatments becomes defined as a mathematical optimisation problem. (27 April, 1983.) 
shape of the time-dependent survival probability z(t).  More precisely, the diagram would be 
obtained by computing the various means of the time-dependent statistical density distributions 
( - z ' )  = -dz /d t  of the lifespan after the various doses F. 
Unfortunately, the laws concerning the dependence of the survival distribution from the 
cytostatic treatment acting simultaneously on the cancer and on its host organism do not appear 
to have been investigated previously, although a large variety of quite heterogeneous experimental 
data concerning this question has been available for many years. 
However, the definition of these laws requires nothing more than a summary analysis of the main 
causal connections (Fig. 3) existing between the few most important and universally recognized 
biological processes whence the instantaneous death risk of an individual is determined at any time 
of his life, and of course, a careful mathematical representation f these processes. In other words, 
we need to establish the network of causes influencing an individual's instantaneous death risk, 
expressed by the ratio - z ' / z .  Now it is clear that the poorer the functional performances of all 
organs and tissues of the individual considered, the higher will be the numerical value assumed by 
this variable. 
In order to achieve a realistic mathematical representation f the whole host-cancer system, 
however, we need to recognize a sharp distinction between the body functions exerted by perennial 
or almost perennial tissues and organs, like the heart, lungs, kidneys or the nervous system, and 
those other functions exerted by cellular or molecular components under continuous renewal, such 
as the leucocytes, cells of the intestinal epithelia, platelets, clotting proteins or antibodies. In 
agreement with such a distinction we may say that any functional impairment will be reversible 
when affecting functions of the latter type, but irreversible otherwise. Moreover, in the following 
the total amount of non-renewable functions will be called the body's "functional redundancy" and 
will be denoted by the symbol r(t), whereas the overall available performance of the renewable 
functions will be denoted by the symbol y(t) .  More details on the meaning of both variables will 
be provided below. 
The causal connections and processes mentioned above may be summarized within the following 
rules: 
I. The instantaneous death risk of an individual is determined by the available 
performance of the main organs and tissues of his body. These fall within two 
main classes: the functions exerted by non-renewable body components and 
those exerted by components under continuous renewal; any functional im- 
pairment will be reversible when affecting the latter functions, and irreversible 
otherwise. 
II. The functional performance r(t)  provided by the non-renewable components 
undergoes large, universally well-experienced changes during the lifespan, since 
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it increases during the growth years and later declines during the middle and 
advanced ages. 
III. On the contrary, the amount y (t) of available deeidous components is under 
the control of a feedback mechanism driving it towards the unit value after any 
displacement of its equilibrium due to contingent vicissitudes. 
IV. A neoplastic cell mass, whenever present, will destroy both kinds of available 
functional efficiency at rates that will be proportional to its size but may vary 
according to the histopathological type of tumor. 
V. Any cytostatic treatment induces biological damage in either the normal or the 
neoplastic tissues. 
These rules are represented schematically in Fig. 2, where the capital letters denote model 
parameters and the lower-case letters express time functions [14]. 
2. THE NATURAL DURATION OF LIFE 
In the simplest mathematical case we need to provide a satisfactory statistical description of the 
human lifespan [15] in the absence of any biological damage produced either by neoplastic diseases 
or cytostatic agents (Fig. 4). 
Under these circumstances we shall ascribe the same functional redundancy r(t)  to all living 
organisms that are threatened by the identical instantaneous death risk - z ' / z  at any time t. This 
implies that a wide range of quite different clinical conditions may be characterized by the same 
value of this variable. However, the quantity r(t)  may also be interpreted as a status indicator for 
the whole collection of non-renewable functional resources of the body: hence it must be high when 
the risk is low and small when the risk is great. 
The highest relative death rates observed within populations of all countries with a high life 
standard occur within the first few days, weeks and months after birth and within the advanced 
ages of the human life. This is certainly due to the low performance r(t)  of all main organs before 
their growth and after their decline (Fig. 5). The instantaneous relative change of this variable must 
be decreasing monotonically throughout the lifespan since the relative body growth has a maximum 
at birth, crosses the zero value when body growth is completed and is followed by the senile decline, 
i.e. by a negative increment of all performances during the middle and advanced ages (Fig. 6). Thus 
we may summarize the above considerations by proposing, for instance, the following formulas 
(Figs 6 and 7): 
r'/r = PQ/ (Q + t) - L (1) 
z ' /z  = - Zr  - R, (2) 
where the capital letters P, Q, L, Z, R denote numerical parameters with obvious biological 
meaning and a well-defined physical dimensionality. 
Equation (1) may be solved under the condition that the maximum of the function r(t),  i.e. the 
value reached at age T = PQ/L  -Q  [obtained by setting r ' (T )= 0 in equation (1)] is expressed 
by the conventionally established value of one human phenotype. This quantity may be conceived 
as a very large amount of information specifying the structure of the organs and of the tissues. 
Thus, we obtain 
r (t) = [(t + Q) / (T  + Q)]m exp[L (T - t)]. (3) 
This expression must replace the symbol r in the above differential equation (1) of the variable z, 
that must also be solved under the initial condition z (0) = 1 if we are interested in establishing the 
relative amount of survivors z (t) at any age t among the people making up the ideal unit population 
at birth. 
By means of this function z( t )  the survival data of the human population of a whole country 
may be fitted with a least-squares minimizing procedure; thus the five parameters can be determined 
with considerable accuracy, the results obtained in three cases are shown in Table 1. 
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Fig. 4. Comparison between the survival experimentally observed [23] within the whole Italian population 
(©) and the corresponding theoretical values (,) obtained by fitting with the mathematical model outlined 
here (see Fig. 3). Experimentally observed (O) and fitted (*) death frequency per year of life in the 
population of Italy 1970-1972 (M + F). Fitting parameters: P = 4.529; Q = 0.0780; L -- 0.02771; 
Z = 0.0004854; R = 4.281. The two functions are expressed as % of the maximum of both. The symbol 
(=) denotes the coincidence of (O) with (,). 
Not  only does the fitting seem to produce an extremely satisfactory result in every case (see the 
example given in Fig. 4) but, also, the numerical coefficients obtained in this way from the mortality 
data may be shown to be fully consistent with various quantitative indications obtained from other 
fields of  research. 
Two independent and rather impressive confirmations of  the above summarized numerical 
results are illustrated in Fig. 5. 
3. THE CYTOKINET IC  MODEL 
Here we shall try to justify the following mathematical description of  the neoplastic cell 
population growth, w(t) being the neoplastic cell population size, roughly corresponding to the 
weight of  the living cancer cells: 
w'/w = .4 - By, (4) 
where A, B express the constant of the spontaneous growth and the coefficient of exponential cell 
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Fig. 5. Comparison between (I) the time-course followed by the functional efficiency r(t) of the 
non-renewable tissues and organs (,), as deduced uniquely from the fitting of the mortality data for the 
Italian population (see Fig. 3), and (II) several other data obtained by direct experimental observation 
and measurements carried out on other populations. G and B denote the increase in bodyweight in girls 
and boys during the first 20 years of life [25], whereas D denotes the maximal breathing capacity during 
the advanced years life according to Shock et al. [26]. 
survival, i.e. the reciprocal of the mean lethal dose; moreover, f = dF/dt  denotes the instantaneous 
intensity of the cytostatic treatment, F(t)  being the total dose administered as a function of time. 
This conclusion cannot be avoided if one assumes that: 
(i) The rate at which the molecular damage m (t) is produced may be set identical 
to the instantaneous intensity of the cytostatic treatment, since the unit of 
measure of m canbe chosen arbitrarily (although it should be expressed as the 
number of elementary chemical changes per cell genome, or more correctly, as 
the number of bits per cell of information loss), whereas the recovery takes place 
according to first-order kinetics: 
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Fig. 6. Time-course of the instantaneous relative increase r'/r in the functional efficiency of the 
"non-renewable" tissues and organs (cf. Fig. 5). The increase has a maximum at birth, vanishes at time 
Twhen the body growth is complete, and falls below this value during the senile decline. The other capital 
letters denote model parameters (see Fig. 3). 
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Fig. 7. Dependence of the instantaneous death risk z'/z from the present functional eliiciency r(t) of the 
"non-renewable" tissues, as deduced from the fitting of the mortality data for the U.S.A. (,) in 1941 and 
the Italian population (O), in 1970-1972 in agreement with the model described here. 
(ii) The cell growth rate is represented by a linear function of the severity of the 
molecular damage, in agreement with the formula 
dw/dt = (A - Jm)w. (6) 
The differential equation (6) implies the occurrence of an instantaneous cell growth whenever 
the severity m (t) of the damage is less than the critical ratio A/J, and an instantaneous reduction 
in the number of living cells whenever the damage m (t) overcomes the same ratio. 
In the case of a damage-free c ll population treated with a dose F administered instantaneously 
at time t = 0, we obtain 
rn (t) = F exp( -  St). (7) 
Hence the amount v (t) of  ceils present after such a treatment will satisfy the differential equation 
dv/dt = [A - J Fexp( -S t ) ]v  with v(0) = w(0), (8) 
which may be solved easily. The solution is 
v (t) = w (0) exp{At + ( JF/S) [exp( -  St) - 1]}. (9) 
However, if we are interested in the long-term consequences of the treatment we need to evaluate 
Table 1. Numerical values of the parameters in equations (1) and (2) obtained by fitting three groups of mortality data drawn from the 
literature [22-24] 
P Q L Z R T=PQ]L -Q r ' (O)=P-L  
U.S.A. 1941 4.211 0.0682 0.02526 0.00152 3.795 11.301 4.186 
Italy 1970-1972 4.529 0.0780 0.02771 0.0004854 4.281 12.671 4.501 
Italy 1974-1977 4.456 0.07872 0.02844 0.000373 4.346 12.255 4.428 
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Fig. 8. Simulated behavior of the cell survival in a split-dose experiment, according to Elkind et al. [16], 
computed by means of the formulas discussed in this paper in Section 3. Cell growth coefficient .4= 
1.38629436 (being the time T expressed in days); healing rate of the molecular damage S = 2.25272834; 
coefficient of cell devitalisation J = 0.0173286795 (= decrea~ of growth rate per unit increase of the 
severity of the molecular lesions). Threshold ose De = .4/J = 80; asymptotic exponential s ope 
B =J/S = 7.69230769E-03 = I/D37 = 1/130rein-equivalents. The diagram drawn by (+) shows the 
computer-simulated colony survival after a treatment with 505 rads followed by a long time interval before 
the second ose of ionizing radiations. The abscissa indicates the total of the two doses. 
the limit I (F)  of the ratio v( t ) /w( t )  between the amount v(t)  of cells present after the treatment 
and the amount 
u (t) = w (0) exp(A t) (10) 
of cells that would have been present at the same time if no treatment had been administered. As 
the time increases this ratio clearly approaches the limit expressed by the negative exponential 
function 
l (F)  = exp( - JV /S )  = exp( -  BF), (11) 
having set 
B = J /S .  (12) 
Since the time needed for recovery of the molecular damage lies several decimal orders of 
magnitude below the time-course of neoplastic diseases, we may consider the relative reduction of 
the cell number induced by the cytostatic treatment as a process that takes place instantaneously. 
Thus justifies the differential equation (4) proposed above. 
However, it is important o emphasize that this description is in full agreement with all the 
available xperimental data [16]. In fact it may be shown that according to the model defined by 
differential equations (5) and (6), the diagram representing the amount of cell colonies grown on 
a solid medium having been plated immediately after the cytostatic treatment would display the 
typical form described in all textbooks of radiation biology (Fig. 8). This is because, according to 
the model, no cell would die for doses below the threshold ratio A/ J - -as  is obvious from equation 
(6), and also from equation (8). For doses F greater than the threshold, however, the colony 
survival is described by the formula 
p (F) = w (0) exp[A/S) log( JF/A ) + (A - JF)/S], (13) 
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As shown by the numerical simulation illustrated in Fig. 8. It may be stressed that the asymptotic 
slope of the survival diagrams obtained from the plating experiments corresponds to the model 
parameter B = J/S, since formula (13) may be rewritten as a function proportional to a Poisson 
distribution of fractional order. 
In the model described here the same consequences are assumed to result from cytostatic 
treatment in the case of: (i) neoplastic ells [expressed by the term (--B f )  in equation (1)]; and 
(ii) normal eucocytes and other deciduous components of the body [term ( -  Cf) in equation (3) 
being B = C]. Nevertheless, in agreement with this model, an overall beneficial effect of the 
treatment may occur, surprisingly, even if the normal and neoplastic cells are characterized bythe 
same identical survival. 
4. THE GENERAL CASE 
In the general case of the survival model we need to introduce a description of the behaviour 
displayed by the amount y(t) of physiological performance exerted by cellular or molecular 
components under continuous renewal. It is obvious that these components wear out at a rate that 
actually changes in time according to a stochastic function, whereas they are produced at a rate 
specified by a feedback loop. In order to describe this in the most concise form we state that under 
equilibrium conditions, i.e. by definition when y (t) equals one average normal human phenotype, 
the deciduous components are produced and destroyed at a certain constant rate, which is of no 
relevance to this model, and that after any displacement from this equilibrium they are restored 
at a rate that is a function of the displacement [1-y(t)] .  This is expressed by the following 
differential equation: 
dy/dt = Ery(1 - y), (14) 
implying a much less immediate recovery for impairments occurring in childhood and in the 
advanced ages, when the quantity r(t) has a lower value. This is the reason for the presence of 
the arrow from block 2 to block 3 in Fig. 3. 
Furthermore, we need to specify the dependence of the instantaneous death risk from the amount 
of deciduous components available at any time. If we assume that for our organism, being 
optimally designed, its functional redundancy has to be homogeneously distributed among all its 
subsystems we are well-justified in the belief that any reduction in performance is almost equally 
dangerous for all organs and tissues. From this consideration one is lead to the choice of a 
symmetric formula such as the following: 
z'/z = --Zr-Ry -r, (15) 
with Y = R. 
The model is defined completely after the introduction of as many as five additional terms that 
specify the destruction caused by the cancer in the non-renewable ( -  Ww) and renewable ( -Dw)  
tissues, the damage produced by the cytostatic treatment in the neoplastic ell mass ( -B f )  and 
in the non-renewable (Vf )  and renewable ( -C f )  functions. 
In conclusion, the four differential equations describing the most general case may be written 
as follows (see Fig. 3): 
and 
w' /w = ary  - By, 
r ' / r  = PQ/ (Q  + t )  - L - V f  - Ww,  
y ' /y  = Er (1  - y )  - C f  - Dw 
(16 or I) 
(17 or II) 
(18 or III) 
z'/z = --Zr-Ry -r. (19 or IV) 
Thus, in equation (16) the relative rate of cancer growth in the absence of damage has been set 
equal to the product of the coefficient A and the two variables r and y in order that it bears a closei 
resemblance to the well-known Gompertzian growth. 
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Fig. 9. Comparison between the survival of irradiated monkeys (O), as observed by Paterson [18] (quoted 
by Duncan and Nias [17]) and the simulated 60-day survival probability (,) of a healthy organism alter 
total body exposure to a single dose of cytostatic treatment. 
Thus, in the case of a neoplastic disease developed from a single cell of the same weight of a 
circulating erythrocyte (about O. 1 ng) that has undergone a neoplastic transformation at time tb 
we may write the following system of initial conditions: 
W(tb) = 10 -1°, 
r(tb) = [(tb + Q)/(T + Q)]eQ exp[L (T -  tb)], [See equation (3)] 
y(tb) = 1, 
z (tb) = 1. 
Under these conditions the function z(t) will define, for t > tb, the survival probability of the 
individual for any possible cytostatic treatment f ( t ) .  
The numerical parameters appearing in the system are the quantities 
P ,Q,L ,Z ,R ,A ,B ,E ,W,D.  
Since we may safely assume that 
V=0,  C=B,  Y=R;  
of these parameters, the first group of five is known with satisfactory accuracy; the coefficient £
may be given the value 26.089 if we assume that the 86% (i.e. [1 -exp( -2) ] )  of hematologic 
impairments induced by the cytostatic treatments, whenever they are not too Serious, are recovered 
within 4 weeks. The quantity A denotes the cancer growth coefficient and has the value of 2.772588 
in the case of a neoplastic disease with a doubling time of 0.25 years. The parameter B for the 
HeLa cells in vitro under aerobic and anaerobic environments assumes values between 1/(400 rad) 
and 1/(140 rad) [17]. However, if we introduce into the model the value of 1/(333 tad), then the 
probability of the survival of the whole organism 2months after the administration of a single doSe 
of cytostatic treatment ranging between I00 and 700 rem-equiv shows excellent agreement with the 
data obtained by Paterson [18] in his experiments on Rhesus monkeys (Fig. 9). 
Furthermore, it may be shown that the model implies a linear relationship between the logarithm 
of the size of the neoplastic ell inoculum and the average lifespan, as experimentally obtained by 
Skipper et al. [19], and that for any positive value of the parameter V the model predicts a linear 
dependence between the total dose of cytostatic agents administered and the shortening of the 
lifespan, as described by Lindop et aL [20] and Storer et al. [21]. Of course, the latter law does not 
apply for extremely high doses of cytostatic agents delivered in a single administration. 
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5. DETERMINATION OF THE CANCER PARAMETERS 
It is clear that a great uncertainty still affects those model parameters that quantify the growth 
rate of the neoplastic cells (A), as well as their two specific destructivities (W, D), despite the above 
attempt to provide an indication of "realistic" or "typical" numerical values. These parameters 
in fact must be expected to assume quite different values in the various clinical cases. Therefore, 
the only way to ascertain the values of these coefficients is by careful analysis of the clinical 
observations. The model described here allows prediction of the patient's urvival; hence the 
necessity to match the model predictions with the actuarial functions observed experimentally. 
Unfortunately, the model does not predict only one survival probability, but as many different and 
time-dependent probability functions as there were clinical cases considered. In fact, even after 
careful selection of an extremely homogeneous set of clinical observations containing N individuals 
bearing the same histological type of neoplastic disease with the same topographic nvolvement, 
and even assuming the existence of values of the model parameters A, W, D common to all 
individuals of the set, the predicted survival of each subject would also be affected by the differing 
ages of onset of the disease, reflected by the initial sizes of the neoplastic ell masses at the time 
of diagnosis, as well as by the different protocols f ( t )  followed in the treatment. 
Therefore, given N > 0 histories of cancer-affected individuals we must consider every clinical 
case as a statistical sample containing only one individual observation that cannot be pooled with 
other similar "samples". Under these conditions we need to introduce a measure d = d(A, W, D) 
of disagreement between the predictions and the corresponding observations that must be adopted 
in place of the total sum of squares commonly used in comparisons between predicted and observed 
survivals within large statistical samples. By searching for the minimum of such a measure of 
disagreement it would be thus possible to asses the numerical values of the oncological coefficients. 
It is clear that the function d(A, IV, D) must be obtained as the sum of the N contributions 
corresponding tothe N individual cases, which is only possible if it is represented bythe logarithm 
of a compound probability. Let us indicate by dr = dr(A, W, D) the contribution of the kth clinical 
case (K = 1, 2 . . . . .  N); moreover, the observed survival of that patient is indicated by SK and the 
model prediction for the survival of the same patient by zK(t). After such premises the solution 
to the problem is represented by the following: 
dr = - In[ - z ~:(Sx)] = - In[-  dzx(Sx)/dt]. 
It may be interesting to point out that if we consider the unlikely case of a large sample on N 
identical individuals characterized bythe same predicted survival z(t) and by an observed lifespan 
distribution i perfect agreement with the prediction, then the above measure of discrepancy simply 
becomes the mathematical entropy of the density distribution z'(t) = dz/dt, or more properly, as 
N increases, it approaches indefinitely the integral 
ft ~ z'(t) In [z'(t)]dt. 
0 
In other words, the ideally complete agreement between the prediction and the observation would 
reduce the measure of discrepancy between prediction and observation to the mere uncertainty 
concerning the time of death of an individual, expressed by the mathematical entropy of the time 
distribution characterizing the lifespan. 
6. THE OPTIMAL TREATMENT 
In order to clarify better the consequences produced by the delivery of any cytostatic agent it 
may be useful to represent them in geometrical terms. Therefore the set X of all possible triplets 
of non-negative quantities w, r, y may be denoted as the vector space of the clinical conditions or 
states where all healthy as well as cancer-affected individuals are properly mapped. Any patient 
may thus be represented by a three-dimensional vector x = (w, r, y) of the space X of the clinical 
conditions. It is clear that two important lines pass through every point x of the space of the 
conditions: these correspond to the two trajectories decribing (i) the change in conditions produced 
by the administration f any dose F of cytostatic agent and (ii) the change in clinical conditions 
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due to the spontaneous evolution of the host-cancer system. As Fincreases, the rate of displacement 
from the point x along the first trajectory is expressed by the vector 
dx/dF = (dw/dF, dr/dF, dy/dF) = ( -  Bw,  - Vr ,  - Cy) ,  
whereas in the course of time t, the rate of displacement from the point x along the second 
trajectory is expressed by the (also age-dependent) vector 
dx/dt = (dw/dt, dr/dt, dy/dt) = {Aw, [PQ/(Q + t) - L - Ww]r, [Er(1 - y )  - Dw]y}.  
It may be noticed that according to formulas (16)-(18) the time changes of the variables w, r, y 
are represented asalgebraic sums of two components each. Every sum consists of a "deterimentar' 
component and a component expressing the recovery from the biological damage produced by the 
cytostatic agents. The former elements of the sums, i.e. the biological damage may be conceived 
as compound erivatives, o that the three differential equations (16)-(18) may now be written in 
vector form: 
dx/d t = dx(tot~,)/d t = (dx/dF) (dF/d t) + dx/dt. 
Moreover, fixing the age t o at diagnosis together with all the parameter values and all other initial 
conditions (being always z0 = 1), and assuming that the finite dose F of cytostatic treatment is
administered instantaneously at this time to, the average patient's urvival s is also defined. The 
latter quantity may be determined by solving the system of differential equations (16-19) and by 
further evaluating the definite integral 
s = z ( t )d t .  
o 
Of course, the average survival s is influenced by a large number of variables including the initial 
patient age to as well as all model parameters. However, it is convenient to represent i as a function 
of the initial conditions w = %, r = to, y = Y0 of the above system of differential equations: 
s = s (w, r, y); 
and it is obvious that the following inequalities are true: 
Os/c)w <0,  Os/Or > O, Os/Oy > O, 
i.e. the greater the neoplastic ell mass, and the lower the available functional efficiencies of the 
two kinds considered here, the lower will be the average patient survival. Therefore, the rate of 
change of the average survival conceived as a function of the total dose F of treatment administered 
instantaneously at time to is expressed as a compound erivative by the scalar product 
q (x)  = ds /dF  = (ds /dx)  (dx/dF) = (Os/Ow) (dw/dF) + (Os/Or) (dr/dF) + (Os/Oy) (dy/dF) 
= - Bw Os/Ow - Vr Os/Or - Cy Os/Oy. 
This derivative may be conveniently denoted by the term "specific usefulness of the cytostatic 
treatment". 
Clearly, the condition 
q(x)  = 0 
defines a surface in the three-dimensional space X of the clinical conditions r0, Y0, w0, whereby the 
space itself is divided in two regions. The average lifespan of the patients lying in one of them (i.e. 
in the region of "untractable" patients, where q < 0) tends to decrease under the effect of the 
administration of the cytostatic agents, whereas the average survival of those lying in the other 
region (i.e. in the region of "tractable" cases, where q > 0) tends to increase under the effect of 
treatment. It may be shown that administration of any dose F of cytostatic agent will tend to 
displace a patient away from this surface if the patient lies in the first region, but will tend to 
displace the patient owards the surface if the patient lies in the latter region. The initial optimal 
dose dF0 represents the exact amount of cytostatic treatment needed to displace one patient from 
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the point where he is found to a point lying exactly on that surface. In fact it is advantageous to 
administer the treatment only as long as the specific usefulness q(x)  remains positive. 
Once given the initial optimal dose F0, however, the model implies the need to administer a
continuous treatment of ever-decreasing intensity f ( t )=  dF/dt. It is easy to understand that the 
optimal intensity of administration of the cytostatic agent is the exact intensity needed to keep a 
patient on the surface q = 0 as long as possible, and it may be shown that the optimal treatment 
intensity must be equal to the following ratio: 
f = dF/dt  = - (dq/dt) / (dq/dF)  
= - { [(dq/dx) (dx/dt )]/[(dq/dx ) (dx/dF)] } 
= - {[(t~q/t~w) (dw/dt)  + (~q/t~r) (dr/dt)  + (t3q/t~y) (dy/dt)] 
/[(t~q /~w ) (dw /dF) + (t~q /t~r ) (dr /dF) + (t~q /t?y ) (dy/dF)]}. 
From a merely computational viewpoint, however, the optimal time distribution of the treatment 
may be determined by decomposing the positive half-line of the time axis in a sequence of intervals 
of equal width h starting from time to, and by determining the optimal amounts 
dF0, dFl, dF2, . . . ,  dFi . . . .  
of cytostatic treatment for each interval, i.e. in the general case, determining the amount 
dF/(i = 0, 1, 2 . . . .  ) required by the instantaneous administration atthe beginning of the ith interval 
in order to maximize the resulting average survival. This technique implies that after the 
determination of the optimal dose dF/for the ith interval (by the method of the bisection or by 
other more efficient algorithms), those consequences of its administration that are going to be 
present at the beginning of the subsequent interval are computed before calculation of the optimal 
dose for the next interval is undertaken. In other words, having obtained the optimal dose dF~ of 
the ith interval, the functions w~(t), ri(t), yi(t), are defined over the ith interval in the following 
way. The numerical values of w., y., r. at the end of the previous interval are considered; these are 
Wo, ro, Y0 
in the case of the first interval (i = 0), and 
Wi_l(to+ih), r~_l(to+ih), y /_ l ( to+ih)  
in the case of any other interval (i > 0). 
The instantaneous consequences of the administration of the optimal dose dF~ at the beginning 
of the interval (t = to + ih) are determined by means of the following formulas: 
wi(to + ih ) + w. exp( -  B dFi) , ri(t o + ih ) = r. exp( -  V dFi) , yi(to + ih ) = y. exp( -  C dE/). 
The spontaneous evolution of the host-cancer system during the ith interval is then calculated 
by solving the system of differential equations (16)-(18) under these initial conditions. The solutions 
obtained in this way are the functions wt(t), r/(t), y/(t). Knowledge of the values assumed by these 
functions at the upper limit of their domain of definition represents the premise for the 
determination of the optimal dose of the subsequent interval. 
In some particular cases, the trivial solution dF~ = 0 for all/-values may be obtained, indicating 
that no advantageous treatment can be applied. This will certainly be true for those points 
x = (w, r, y) in the region of untractable patients where the time derivative of the variable y in the 
absence of treatment, i.e. dy/dt, has a value less than or equal to zero (which means an irreversible 
untractability). In other words, the optimal treatment will assume a trivial value at least for all 
points x where the following two inequalities are simultaneously satisfied: 
q<0,  and dy /dt<0.  
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